Canada-based Willow Biosciences (CSE: WLLW) was recently featured in a video by InvestmentPitch Media detailing how the company utilizes its proprietary biosynthetic processes to deliver high yields of ultra-pure, low-cost cannabinoids. An article further discussing the company reads, “The video (http://nnw.fm/ebN5C) highlights a recent joint development agreement between Alberta, Canada-based Willow Biosciences and Delaware-headquartered Noramco that will build on Willow’s experience in developing manufacturing processes for active pharmaceutical ingredients (‘APIs’) that treat conditions such as cancer, pain and central nervous system disorders, as well as Noramco’s experience in producing high-quality, synthetic cannabinoid APIs for the pharmaceutical and health care industry. . . . Under the agreement, Willow will focus on developing ultra-pure CBD with its pioneering biosynthetic technology, bypassing the costs and waste associated with plant cultivation for a single cannabinoid by optimizing yeast cultivation processes, while Noramco will be responsible for the scale-up, regulatory applications, marketing and distribution of the companies’ products. Their work has the potential to open new and larger markets for CBD and related compounds, as well as providing low-cost solutions to pharmaceutical partners.”
To view the full article, visit http://nnw.fm/0r7WM
About Willow Biosciences Inc.
Headquartered in Calgary, Canada, Willow and its team of scientists are leaders in the field of biosynthetic production of high-value, plant-derived compounds. Willow has applied its integrated suite of technologies to develop manufacturing processes for numerous active pharmaceutical ingredients with various therapeutic benefits, including cancer treatment, pain management and CNS disorders. In the cannabinoid field, Willow owns proprietary, yeast-based lab strains that produce CBD, tetrahydrocannabinol (THC) and cannabigerol (CBG), as well as certain minor and novel cannabinoids. For more information, visit the company’s website at www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://nnw.fm/WLLW
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
